Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia

by Madero‐Marroquin, Rafael , Shah, Syed , Saygin, Caner , Gurbuxani, Sandeep , Patel, Anand A. , Hunter, Ryan W. , Stock, Wendy , DuVall, Adam S. , Rahmani Youshanlouei, Hamed , Johnston, Hannah , Osei, Clinton

in acute leukemia / Acute lymphoblastic leukemia / ALL / Antibodies / CD58 / CD58 antigen / Cell activation / Cell therapy / Chimeric antigen receptors / Drug dosages / Flow cytometry / inotuzumab ozogamicin / Leukemia / Lymphatic leukemia / Patients / Regression analysis / Remission (Medicine) / Response rates / Short Report

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia

2025

Confirm

Do you wish to request the book?

CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia

Madero‐Marroquin, Rafael,

Shah, Syed,

Saygin, Caner,

Gurbuxani, Sandeep,

Patel, Anand A.,

Hunter, Ryan W.,

Stock, Wendy,

DuVall, Adam S.,

Rahmani Youshanlouei, Hamed,

Johnston, Hannah,

Osei, Clinton

2025

Overview

Background CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T‐cell therapy, functioning as a modulator of response to T‐cell activation. Methods Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B‐cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO). Results The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI. Conclusion Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.

Share this book

Add to My Shelf

Publisher

John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley

Subject

acute leukemia

/ Acute lymphoblastic leukemia

/ ALL

/ Antibodies

/ CD58

/ CD58 antigen

/ Cell activation